Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAT | P00750 | 9/20 | 0.51 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14264666 | 0.80 | PLAT (0.53) | PLATKDM4DKDM4EALDH1A1 | |
| SCHEMBL8226808 | 0.76 | KDM4E (0.49) | MAPTKDM4EALDH1A1GAA | |
| SCHEMBL9468732 | 0.76 | KDM4E (0.64) | KDM4DMAPTKDM4EALDH1A1GAA | |
| SCHEMBL11735776 | 0.68 | ALDH1A1 (0.59) | MAPTIDO1KDM4EALDH1A1GAA | |
| SCHEMBL17738495 | 0.68 | PLAT (1.00) | PLAT | |
| SCHEMBL6435365 | 0.66 | TSHR (0.53) | MAPTIDO1ALDH1A1 | |
| SCHEMBL10887360 | 0.65 | KDM4E (0.63) | MAPTIDO1KDM4EALDH1A1 | |
| SCHEMBL12953361 | 0.65 | KDM4E (0.43) | PLATKDM4DMAPTKDM4EALDH1A1 | |
| SCHEMBL17821034 | 0.65 | PLAT (0.46) | PLATKDM4DKDM4EALDH1A1 | |
| SCHEMBL7276378 | 0.65 | LMNA (0.52) | MAPTKDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080058351-A1 | Deuterated pyrazolo(1,5-a)pyrimidine compounds; sedative or hypnotic agents; sleep disorders such as insomnia; modulating a GABA receptor-chloride ionophore complex in a cell through binding to the neurosteroid site on the complex | CONCERT PHARMACEUTICALS INC. (US) | 2008-03-06 | — | — | US | disclosed |
| WO-2008005471-A2 | NOVEL HETEROBICYCLIC COMPOUNDS | CONCERT PHARMACEUTICALS INC. (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058351-A1 | Deuterated pyrazolo(1,5-a)pyrimidine compounds; sedative or hypnotic agents; sleep disorders such as insomnia; modulating a GABA receptor-chloride ionophore complex in a cell through binding to the neurosteroid site on the complex | GABRA5, GABRA1, GABRA4 | PLAT 4164/4885KDM4D 2581/4885MAPT 3592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.